High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial)

Sahajal Dhooria, Shivani Chaudhary, Inderpaul Singh Sehgal, Ritesh Agarwal, Siddhant Arora, Mandeep Garg, Nidhi Prabhakar, Goverdhan Dutt Puri, Ashish Bhalla, Vikas Suri, Lakshmi Narayana Yaddanapudi, Valliappan Muthu, Kuruswamy Thurai Prasad, Ashutosh Nath Aggarwal, Sahajal Dhooria, Shivani Chaudhary, Inderpaul Singh Sehgal, Ritesh Agarwal, Siddhant Arora, Mandeep Garg, Nidhi Prabhakar, Goverdhan Dutt Puri, Ashish Bhalla, Vikas Suri, Lakshmi Narayana Yaddanapudi, Valliappan Muthu, Kuruswamy Thurai Prasad, Ashutosh Nath Aggarwal

Abstract

High-dose prednisolone may not be superior to a low-dose 6-week regimen in improving clinical, physiological and radiological outcomes, or health-related quality of life, in patients with symptomatic post-COVID-19 diffuse parenchymal lung abnormalities https://bit.ly/32zqnXt

Trial registration: ClinicalTrials.gov NCT04657484.

Conflict of interest statement

Conflict of interest: None declared.

References

    1. Montani D, Savale L, Beurnier A, et al. . Multidisciplinary approach for post-acute COVID-19 syndrome: time to break down the walls. Eur Respir J 2021; 58: 2101090. doi:10.1183/13993003.01090-2021
    1. Garg M, Maralakunte M, Garg S, et al. . The conundrum of ‘long-COVID-19’: a narrative review. Int J Gen Med 2021; 14: 2491–2506. doi:10.2147/IJGM.S316708
    1. Funke-Chambour M, Bridevaux PO, Clarenbach CF, et al. . Swiss recommendations for the follow-up and treatment of pulmonary long COVID. Respiration 2021; 100: 826–841. doi:10.1159/000517255
    1. Myall KJ, Mukherjee B, Castanheira AM, et al. . Persistent post-COVID-19 interstitial lung disease. An observational study of corticosteroid treatment. Ann Am Thorac Soc 2021; 18: 799–806. doi:10.1513/AnnalsATS.202008-1002OC
    1. Kostorz-Nosal S, Jastrzębski D, Chyra M, et al. . A prolonged steroid therapy may be beneficial in some patients after the COVID-19 pneumonia. Eur Clin Respir J 2021; 8: 1945186. doi:10.1080/20018525.2021.1945186
    1. Segala FV, Sgalla G, Salvati F, et al. . Adjunctive corticosteroid treatment for organizing pneumonia in COVID-19 patients with persistent respiratory failure. Respir Med 2021; 187: 106571. doi:10.1016/j.rmed.2021.106571
    1. Miller MR, Hankinson J, Brusasco V, et al. . Standardisation of spirometry. Eur Respir J 2005; 26: 319–338. doi:10.1183/09031936.05.00034805
    1. Holland AE, Spruit MA, Troosters T, et al. . An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J 2014; 44: 1428–1446. doi:10.1183/09031936.00150314
    1. Hinchcliff M, Beaumont JL, Thavarajah K, et al. . Validity of two new patient-reported outcome measures in systemic sclerosis: Patient-Reported Outcomes Measurement Information System 29-item Health Profile and Functional Assessment of Chronic Illness Therapy-Dyspnea short form. Arthritis Care Res 2011; 63: 1620–1628. doi:10.1002/acr.20591
    1. Patel AS, Siegert RJ, Brignall K, et al. . The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax 2012; 67: 804–810. doi:10.1136/thoraxjnl-2012-201581
    1. Sinha R, van den Heuvel WJ, Arokiasamy P. Validity and reliability of MOS short form health survey (SF-36) for use in India. Indian J Community Med 2013; 38: 22–26. doi:10.4103/0970-0218.106623
    1. Petitpierre N, Cottin V, Marchand-Adam S, et al. . A 12-week combination of clarithromycin and prednisone compared to a 24-week prednisone alone treatment in cryptogenic and radiation-induced organizing pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2018; 35: 230–238.
    1. Wu X, Liu X, Zhou Y, et al. . 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med 2021; 9: 747–754. doi:10.1016/S2213-2600(21)00174-0
    1. González J, Benítez ID, Carmona P, et al. . Pulmonary function and radiologic features in survivors of critical COVID-19: a 3-month prospective cohort. Chest 2021; 160: 187–198. doi:10.1016/j.chest.2021.02.062
    1. Shah AS, Wong AW, Hague CJ, et al. . A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations. Thorax 2021; 76: 402–404. doi:10.1136/thoraxjnl-2020-216308

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi